Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to the therapeutic use of donated healthy red blood cells in the context of the TAPS2 (Transfusion Antenatally in Pregnant Women with Sickle Cell Disease) trial conducted by Guy's and St Thomas' NHS Foundation Trust. The intervention involves serial prophylactic exchange blood transfusion (SPEBT) using automated apheresis technology. This procedure mechanically removes the patient's sickle-shaped red blood cells and simultaneously replaces them with healthy donor red blood cells containing normal hemoglobin A. The primary therapeutic goal is to maintain the percentage of hemoglobin S (HbS%) below 30% throughout pregnancy to prevent vaso-occlusive crises and improve both maternal and infant outcomes, such as reducing the risk of pre-eclampsia and fetal growth restriction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red blood cells-Guy's and St Thomas' NHS Foundation Trust-sickle cell disease.